ATLANTA, GA (Nov. 1, 2018) – Rimidi, an Atlanta-based healthcare technology company, today announced a partnership with PTS Diagnostics, a leading manufacturer of point-of-care biometric testing devices. Together, the two companies seek to close gaps in care, drive clinical efficiency and improve patient outcomes with Connected Care, a digital condition management solution powered by Rimidi’s software.
Rimidi’s software enables personalized, virtual management for individuals with cardiometabolic diseases, and offers population analytics, clinical data and predictive medication modeling for providers. The joint offering of Rimidi and PTS Diagnostics A1CNow® and CadioCheck® point-of-care patient test systems enables the type of proactive population management required for value-based care models. “Rimidi’s goal is to improve the experience for both patients with chronic conditions and their physicians and care teams, ultimately improving patient outcomes and lowering costs,” said Josh Claman, CEO of Rimidi. “We believe an ecosystem of strategic partnerships like this one with PTS Diagnostics is crucial to achieving our mission.”
With unique digital dashboards for both patients and providers, Connected Care allows for remote patient monitoring and coaching. Unlike other freestanding chronic disease management platforms, Connected Care works seamlessly into the physician or care team’s workflow, integrating directly with providers’ Electronic Health Records (EHRs), leveraging emerging industry standards like SMART on FHIR.
“PTS Diagnostics has spent considerable time and effort understanding our customer’s needs related to patient outcomes, workflow improvement, and maximizing value-based payment models,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We’ve partnered with Rimidi to better serve our customers when it comes to improved patient and provider experience and outcomes at a lower cost.” This partnership is being unveiled in the United States and select foreign countries and will continue to grow as population health needs dictate. For more information, please reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS customer service at firstname.lastname@example.org for more information.
Rimidi is addressing the healthcare problem of our generation—cardiometabolic diseases, which account for 70 percent of healthcare spending. Created by doctors, Rimidi enables efficient personalized care to forward the future of healthcare. Rimidi’s platform derives actionable insight for clinicians and care teams from individual patient data, and integrates seamlessly into provider EHR systems, optimizing clinical workflow, improving health outcomes, and reducing costs. To learn more, visit Rimidi.com .
About PTS Diagnostics
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.
Ryan Simpson, Senior Marketing Associate, PTS Diagnostics
Emily Keough, Senior Marketing Manager, Rimidi